Developing Clinical Pathways for Treatment of Advanced/Metastatic ccRCC in Managed Care Pharmacy: Opportunities, Challenges, and Best Practices

This activity was originally broadcast live as a symposium at AJMC® Day of Education 2022.

Program Description

Over the past several years, multiple targeted agents and immunotherapies for treatment of clear cell renal cell carcinoma (ccRCC) have been approved and are recommended for use in patients with advanced/metastatic disease, including monotherapies and combinations of agents, with guideline recommendations basing the principles of systemic therapy on favorable versus poor/intermediate risk. As the demand to curb healthcare costs and provide more transparency related to clinical outcomes has grown along with the complexity of precision medicine, payers are focusing on strategies that will promote care quality and value while controlling costs. One such strategy is the use of oncology pathways in clinical practice. Because of the rising interest in oncology clinical pathway use, it is imperative that managed care pharmacists better delineate current, new, and emerging treatment strategies for advanced/metastatic ccRCC. This program will explore the economics associated with these strategies and offer practice approaches for managed care professionals to recognize the effects of utilizing clinical pathways to individualize patient treatment and optimize overall outcomes in ccRCC.

Target audience: Oncology pharmacists and managed care pharmacists

Type of activity: Application
Release date: November 1, 2022
Expiration date: November 1, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare current and evolving guidelines and other recommendations for use of targeted agents and immunotherapies for advanced/metastatic clear cell renal cell carcinoma (ccRCC).
• Classify evolving management tools for optimizing pharmacotherapy for advanced/metastatic ccRCC while reducing costs of treatment.
• Explain the key criteria and factors for optimal clinical pathway development, implementation, and use in treatment of patients with advanced/metastatic ccRCC.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-549-H01-P. The activity is available for CE credit through November 1, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Sherry L. Vogt, PharmD, BCOP; and Laura R. Bobolts, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Amy Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms